JP2017526747A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017526747A5 JP2017526747A5 JP2017530956A JP2017530956A JP2017526747A5 JP 2017526747 A5 JP2017526747 A5 JP 2017526747A5 JP 2017530956 A JP2017530956 A JP 2017530956A JP 2017530956 A JP2017530956 A JP 2017530956A JP 2017526747 A5 JP2017526747 A5 JP 2017526747A5
- Authority
- JP
- Japan
- Prior art keywords
- manufacturing process
- process according
- crystallized particles
- mixture
- temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 8
- 238000000265 homogenisation Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 17
- 239000002245 particle Substances 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 5
- 239000011259 mixed solution Substances 0.000 claims 5
- 238000001816 cooling Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 238000003756 stirring Methods 0.000 claims 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims 1
- 229940011051 isopropyl acetate Drugs 0.000 claims 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462041341P | 2014-08-25 | 2014-08-25 | |
| US62/041,341 | 2014-08-25 | ||
| PCT/US2015/046525 WO2016032950A1 (en) | 2014-08-25 | 2015-08-24 | Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019169473A Division JP2019210296A (ja) | 2014-08-25 | 2019-09-18 | 統合失調症治療用の持続放出型製剤におけるアリピプラゾール誘導体の結晶化プロセス |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017526747A JP2017526747A (ja) | 2017-09-14 |
| JP2017526747A5 true JP2017526747A5 (cg-RX-API-DMAC7.html) | 2019-09-12 |
| JP6591546B2 JP6591546B2 (ja) | 2019-10-16 |
Family
ID=55347322
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017530956A Active JP6591546B2 (ja) | 2014-08-25 | 2015-08-24 | 統合失調症治療用の持続放出型製剤におけるアリピプラゾール誘導体の結晶化プロセス |
| JP2019169473A Pending JP2019210296A (ja) | 2014-08-25 | 2019-09-18 | 統合失調症治療用の持続放出型製剤におけるアリピプラゾール誘導体の結晶化プロセス |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019169473A Pending JP2019210296A (ja) | 2014-08-25 | 2019-09-18 | 統合失調症治療用の持続放出型製剤におけるアリピプラゾール誘導体の結晶化プロセス |
Country Status (20)
| Country | Link |
|---|---|
| US (5) | US10064859B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3865476B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6591546B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN107106556B (cg-RX-API-DMAC7.html) |
| AU (2) | AU2015306910B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2959329C (cg-RX-API-DMAC7.html) |
| CY (1) | CY1124058T1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3185867T3 (cg-RX-API-DMAC7.html) |
| ES (2) | ES2994850T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20210551T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE054641T2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL250661B (cg-RX-API-DMAC7.html) |
| LT (1) | LT3185867T (cg-RX-API-DMAC7.html) |
| MA (2) | MA40480B1 (cg-RX-API-DMAC7.html) |
| PL (1) | PL3185867T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3185867T (cg-RX-API-DMAC7.html) |
| RS (1) | RS61709B1 (cg-RX-API-DMAC7.html) |
| SI (1) | SI3185867T1 (cg-RX-API-DMAC7.html) |
| SM (1) | SMT202100212T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016032950A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ631345A (en) | 2012-09-19 | 2017-06-30 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions having improved storage stability |
| US10016415B2 (en) | 2014-08-18 | 2018-07-10 | Alkermes Pharma Ireland Limited | Aripiprazole prodrug compositions |
| CA2959329C (en) * | 2014-08-25 | 2023-06-27 | Alkermes Pharma Ireland Limited | Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia |
| EP3294724A4 (en) * | 2015-05-08 | 2018-11-21 | Davuluri, Ramamohan Rao | Improved process for the preparation of aripiprazole with reduced particle size |
| WO2018104953A1 (en) * | 2016-12-07 | 2018-06-14 | Msn Laboratories Private Limited, R&D Center | Improved process for the preparation of 7-{4-[4-(2,3-dichlorophenyl)-piperazin-1-yl]butoxy}-2oxo-3,4-dihydro-2h-quinolin-1-yl)methyl dodecanoate |
| ES2903278T3 (es) | 2017-07-28 | 2022-03-31 | Interquim Sa | Procedimiento para la preparación de aripiprazol lauroxil |
| CN110218209B (zh) * | 2018-03-02 | 2022-09-30 | 上海现代药物制剂工程研究中心有限公司 | 一种依匹哌唑月桂酸酯的晶型a、其制备方法及应用 |
| CA3092335A1 (en) | 2018-03-05 | 2019-09-12 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
| CN113105389B (zh) * | 2021-04-16 | 2022-04-08 | 江苏海洋大学 | 一种阿立哌唑药物共晶及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5510118A (en) * | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| AR033485A1 (es) * | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| US20050032811A1 (en) | 2003-08-06 | 2005-02-10 | Josiah Brown | Methods for administering aripiprazole |
| JP4836797B2 (ja) * | 2003-10-23 | 2011-12-14 | 大塚製薬株式会社 | 放出制御性無菌注射アリピプラゾール製剤および方法 |
| TWI371274B (en) * | 2003-10-23 | 2012-09-01 | Bristol Myers Squibb Co | Process for making sterile aripiprazole of desired mean particle size |
| KR102318070B1 (ko) | 2007-12-19 | 2021-10-27 | 얀센 파마슈티카 엔.브이. | 장기 작용성 주사가능 팔리페리돈 에스테르와 관련된 투여 요법 |
| US20110003823A1 (en) | 2008-08-01 | 2011-01-06 | Alpha Synergy Development, Inc. | Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage |
| PL2445502T5 (pl) | 2009-06-25 | 2023-03-13 | Alkermes Pharma Ireland Limited | Związki heterocykliczne do leczenia zaburzeń neurologicznych i psychologicznych |
| WO2012077134A1 (en) * | 2010-12-07 | 2012-06-14 | Ind-Swift Laboratories Limted | Process for preparing aripiprazole polymorphs |
| AU2012204174B2 (en) * | 2011-01-07 | 2016-07-21 | Neodyne Biosciences, Inc. | Wound or skin treatment devices and methods |
| PL2685979T3 (pl) * | 2011-03-18 | 2017-02-28 | Alkermes Pharma Ireland Limited | Kompozycje farmaceutyczne do wstrzykiwania zawierające środek nierozpuszczalny w wodzie, środek przeciwpsychotyczny, laurynian sorbitanu i polisorbat 20 |
| EP2827868B8 (en) * | 2012-03-19 | 2019-12-18 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty acid esters |
| NZ631345A (en) * | 2012-09-19 | 2017-06-30 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions having improved storage stability |
| CA2959329C (en) * | 2014-08-25 | 2023-06-27 | Alkermes Pharma Ireland Limited | Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia |
-
2015
- 2015-08-24 CA CA2959329A patent/CA2959329C/en active Active
- 2015-08-24 SM SM20210212T patent/SMT202100212T1/it unknown
- 2015-08-24 EP EP21150116.8A patent/EP3865476B1/en active Active
- 2015-08-24 SI SI201531576T patent/SI3185867T1/sl unknown
- 2015-08-24 PT PT158364315T patent/PT3185867T/pt unknown
- 2015-08-24 US US14/833,638 patent/US10064859B2/en active Active
- 2015-08-24 HU HUE15836431A patent/HUE054641T2/hu unknown
- 2015-08-24 CN CN201580057857.XA patent/CN107106556B/zh active Active
- 2015-08-24 ES ES21150116T patent/ES2994850T3/es active Active
- 2015-08-24 MA MA40480A patent/MA40480B1/fr unknown
- 2015-08-24 ES ES15836431T patent/ES2862098T3/es active Active
- 2015-08-24 EP EP15836431.5A patent/EP3185867B1/en active Active
- 2015-08-24 WO PCT/US2015/046525 patent/WO2016032950A1/en not_active Ceased
- 2015-08-24 MA MA055917A patent/MA55917A/fr unknown
- 2015-08-24 RS RS20210433A patent/RS61709B1/sr unknown
- 2015-08-24 HR HRP20210551TT patent/HRP20210551T1/hr unknown
- 2015-08-24 JP JP2017530956A patent/JP6591546B2/ja active Active
- 2015-08-24 LT LTEP15836431.5T patent/LT3185867T/lt unknown
- 2015-08-24 CN CN202010375290.3A patent/CN111454207B/zh active Active
- 2015-08-24 AU AU2015306910A patent/AU2015306910B2/en active Active
- 2015-08-24 PL PL15836431T patent/PL3185867T3/pl unknown
- 2015-08-24 DK DK15836431.5T patent/DK3185867T3/da active
-
2017
- 2017-02-19 IL IL250661A patent/IL250661B/en active IP Right Grant
-
2018
- 2018-07-24 US US16/043,721 patent/US10478434B2/en active Active
-
2019
- 2019-09-18 JP JP2019169473A patent/JP2019210296A/ja active Pending
- 2019-10-08 US US16/595,608 patent/US10973816B2/en active Active
-
2020
- 2020-11-04 AU AU2020264303A patent/AU2020264303B2/en active Active
-
2021
- 2021-03-24 US US17/211,352 patent/US11883394B2/en active Active
- 2021-04-13 CY CY20211100318T patent/CY1124058T1/el unknown
-
2023
- 2023-12-18 US US18/543,767 patent/US20240245676A1/en active Pending